Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 204

1.

[Myositis: more than a muscle disease].

Lim J, van Royen-Kerkhof A, Jonkers RE, Starink MV, Voskuyl AE, van der Kooi AJ.

Ned Tijdschr Geneeskd. 2018;162(0):D2312. Dutch.

PMID:
29473539
2.

Bone formation in ankylosing spondylitis during anti-tumour necrosis factor therapy imaged by 18F-fluoride positron emission tomography.

Bruijnen STG, Verweij NJF, van Duivenvoorde LM, Bravenboer N, Baeten DLP, van Denderen CJ, van der Horst-Bruinsma IE, Voskuyl AE, Custers M, van de Ven PM, Bot JCJ, Boden BJH, Lammertsma AA, Hoekstra OSH, Raijmakers PGHM, van der Laken CJ.

Rheumatology (Oxford). 2018 Apr 1;57(4):770. doi: 10.1093/rheumatology/key034. No abstract available.

3.

Bone formation in ankylosing spondylitis during anti-tumour necrosis factor therapy imaged by 18F-fluoride positron emission tomography.

Bruijnen STG, Verweij NJF, van Duivenvoorde LM, Bravenboer N, Baeten DLP, van Denderen CJ, van der Horst-Bruinsma IE, Voskuyl AE, Custers M, van de Ven PM, Bot JCJ, Boden BJH, Lammertsma AA, Hoekstra OSH, Raijmakers PGHM, van der Laken CJ.

Rheumatology (Oxford). 2018 Apr 1;57(4):631-638. doi: 10.1093/rheumatology/kex448. Erratum in: Rheumatology (Oxford). 2018 Apr 1;57(4):770.

4.

Relation between duration of the prodromal phase and renal damage in ANCA-associated vasculitis.

Houben E, Groenland SL, van der Heijden JW, Voskuyl AE, Doodeman HJ, Penne EL.

BMC Nephrol. 2017 Dec 29;18(1):378. doi: 10.1186/s12882-017-0797-x.

5.

Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial.

Ter Wee MM, Coupé VM, den Uyl D, Blomjous BS, Kooijmans E, Kerstens PJ, Nurmohamed MT, van Schaardenburg D, Voskuyl AE, Boers M, Lems WF.

RMD Open. 2017 Oct 25;3(2):e000502. doi: 10.1136/rmdopen-2017-000502. eCollection 2017.

6.

Maternal and Perinatal Outcome in Women with Systemic Lupus Erythematosus: A Retrospective Bicenter Cohort Study.

Kroese SJ, Abheiden CNH, Blomjous BS, van Laar JM, Derksen RWHM, Bultink IEM, Voskuyl AE, Lely AT, de Boer MA, de Vries JIP, Fritsch-Stork RDE.

J Immunol Res. 2017;2017:8245879. doi: 10.1155/2017/8245879. Epub 2017 Sep 28.

7.

Comprehensive approach to study complement C4 in systemic lupus erythematosus: Gene polymorphisms, protein levels and functional activity.

Tsang-A-Sjoe MWP, Bultink IEM, Korswagen LA, van der Horst A, Rensink I, de Boer M, Hamann D, Voskuyl AE, Wouters D.

Mol Immunol. 2017 Dec;92:125-131. doi: 10.1016/j.molimm.2017.10.004. Epub 2017 Oct 26.

PMID:
29080553
8.

Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies.

Houben E, Penne EL, Voskuyl AE, van der Heijden JW, Otten RHJ, Boers M, Hoekstra T.

Rheumatology (Oxford). 2018 Mar 1;57(3):555-562. doi: 10.1093/rheumatology/kex338. Review.

PMID:
29029294
9.

Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial.

Konijn NPC, van Tuyl LHD, Boers M, den Uyl D, Ter Wee MM, van der Wijden LKM, Bultink IEM, Kerstens PJSM, Voskuyl AE, van Schaardenburg D, Nurmohamed MT, Lems WF.

Rheumatology (Oxford). 2017 Sep 1;56(9):1586-1596. doi: 10.1093/rheumatology/kex223.

PMID:
28859326
10.

Variability in quantitative analysis of atherosclerotic plaque inflammation using 18F-FDG PET/CT.

Lensen KDF, van Sijl AM, Voskuyl AE, van der Laken CJ, Heymans MW, Comans EFI, Nurmohamed MT, Smulders YM, Boellaard R.

PLoS One. 2017 Aug 11;12(8):e0181847. doi: 10.1371/journal.pone.0181847. eCollection 2017.

11.

An MIF Promoter Polymorphism Is Associated with Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis.

Bossini-Castillo L, Campillo-Davó D, López-Isac E, Carmona FD, Simeon CP, Carreira P, Callejas-Rubio JL, Castellví I, Fernández-Nebro A, Rodríguez-Rodríguez L, Rubio-Rivas M, García-Hernández FJ, Madroñero AB, Beretta L, Santaniello A, Lunardi C, Airó P, Hoffmann-Vold AM, Kreuter A, Riemekasten G, Witte T, Hunzelmann N, Vonk MC, Voskuyl AE, de Vries-Bouwstra J, Shiels P, Herrick A, Worthington J, Radstake TRDJ, Martin J; Spanish Scleroderma Group.

J Rheumatol. 2017 Oct;44(10):1453-1457. doi: 10.3899/jrheum.161369. Epub 2017 Jul 1.

PMID:
28668810
12.

Protein array autoantibody profiles to determine diagnostic markers for neuropsychiatric systemic lupus erythematosus.

van der Meulen PM, Barendregt AM, Cuadrado E, Magro-Checa C, Steup-Beekman GM, Schonenberg-Meinema D, Van den Berg JM, Li QZ, Baars PA, Wouters D, Voskuyl AE, Ten Berge IRJM, Huizinga TWJ, Kuijpers TW.

Rheumatology (Oxford). 2017 Aug 1;56(8):1407-1416. doi: 10.1093/rheumatology/kex073.

PMID:
28460084
13.

A multi-parameter response prediction model for rituximab in rheumatoid arthritis.

de Jong TD, Sellam J, Agca R, Vosslamber S, Witte BI, Tsang-A-Sjoe M, Mantel E, Bijlsma JW, Voskuyl AE, Nurmohamed MT, Verweij CL, Mariette X.

Joint Bone Spine. 2018 Mar;85(2):219-226. doi: 10.1016/j.jbspin.2017.02.015. Epub 2017 Mar 28.

PMID:
28363827
14.

Prevalence of malnutrition and validation of bioelectrical impedance analysis for the assessment of body composition in patients with systemic sclerosis.

Spanjer MJ, Bultink IEM, de van der Schueren MAE, Voskuyl AE.

Rheumatology (Oxford). 2017 Jun 1;56(6):1008-1012. doi: 10.1093/rheumatology/kex014.

PMID:
28340004
15.

Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project.

van den Oever IAM, Heslinga M, Griep EN, Griep-Wentink HRM, Schotsman R, Cambach W, Dijkmans BAC, Smulders YM, Lems WF, Boers M, Voskuyl AE, Peters MJL, van Schaardenburg D, Nurmohamed MT.

Rheumatology (Oxford). 2017 Sep 1;56(9):1472-1478. doi: 10.1093/rheumatology/kew497.

PMID:
28199724
16.

Analysis of ATP8B4 F436L Missense Variant in a Large Systemic Sclerosis Cohort.

López-Isac E, Bossini-Castillo L, Palma AB, Assassi S, Mayes MD, Simeón CP, Ortego-Centeno N, Vicente E, Tolosa C, Rubio-Rivas M, Román-Ivorra JA, Beretta L, Moroncini G, Hunzelmann N, Distler JHW, Riemekasten G, de Vries-Bouwstra J, Voskuyl AE, Radstake TRDJ, Herrick A, Denton CP, Fonseca C, Martín J.

Arthritis Rheumatol. 2017 Jun;69(6):1337-1338. doi: 10.1002/art.40058. Epub 2017 May 9. No abstract available.

17.

Screening for renal involvement in ANCA-associated vasculitis: room for improvement?

Houben E, van der Heijden JW, van Dam B, Bax WA, Voskuyl AE, Penne EL.

Neth J Med. 2017 Jan;75(1):21-26.

18.

Anti-Hinge Antibodies Recognize IgG Subclass- and Protease-Restricted Neoepitopes.

Falkenburg WJ, van Schaardenburg D, Ooijevaar-de Heer P, Tsang-A-Sjoe MW, Bultink IE, Voskuyl AE, Bentlage AE, Vidarsson G, Wolbink G, Rispens T.

J Immunol. 2017 Jan 1;198(1):82-93. Epub 2016 Nov 18.

19.

Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus.

Tsang-A-Sjoe MW, Bultink IE, Heslinga M, Voskuyl AE.

Rheumatology (Oxford). 2017 Jan;56(1):121-128. doi: 10.1093/rheumatology/kew377. Epub 2016 Nov 1.

PMID:
27803306
20.

Do Short and Sustained Periods of American College of Rheumatology/European League Against Rheumatism Remission Predict Functional and Radiographic Outcome in Early Rheumatoid Arthritis Patients With Low Overall Damage Progression?

Konijn NPC, van Tuyl LHD, Boers M, den Uyl D, Ter Wee MM, Kerstens P, Voskuyl AE, van Schaardenburg D, Nurmohamed MT, Lems WF.

Arthritis Care Res (Hoboken). 2017 Jul;69(7):989-996. doi: 10.1002/acr.23112. Epub 2017 Jun 7.

PMID:
27696732

Supplemental Content

Loading ...
Support Center